Advancement of global health: key messages from the Disease Control Priorities Project

@article{Laxminarayan2006AdvancementOG,
  title={Advancement of global health: key messages from the Disease Control Priorities Project},
  author={R. Laxminarayan and A. Mills and J. Breman and A. Measham and G. Alleyne and M. Claeson and P. Jha and P. Musgrove and Jeffrey T Y Chow and Sonbol A. Shahid-Salles and D. Jamison},
  journal={The Lancet},
  year={2006},
  volume={367},
  pages={1193-1208}
}
The Disease Control Priorities Project (DCPP), a joint project of the Fogarty International Center of the US National Institutes of Health, the WHO, and The World Bank, was launched in 2001 to identify policy changes and intervention strategies for the health problems of low-income and middle-income countries. Nearly 500 experts worldwide compiled and reviewed the scientific research on a broad range of diseases and conditions, the results of which are published this week. A major product of… Expand

Figures, Tables, and Topics from this paper

Paper Mentions

Disease Control Priorities, 3rd edition: improving health and reducing poverty
TLDR
One way health systems achieve expanded intervention coverage is through investing in platforms that deliver interventions that require similar logistics, but which address heterogeneous health problems, which can often provide a more helpful guide to health-system investments than can analysis only of interventions. Expand
Health metrics and evaluation: strengthening the science
TLDR
In depth topics with major scientific challenges and institutional and cultural barriers that are slowing the development of the field are explored. Expand
Disease Control Priorities Third Edition Is Published: A Theory of Change Is Needed for Translating Evidence to Health Policy
  • O. Norheim
  • Business, Medicine
  • International journal of health policy and management
  • 2018
TLDR
Some of the relevant factors needed to develop a Theory of Change for translating economic evidence to better priority setting within countries are discussed, and some key strategic choices that are necessary to achieve the desired outputs and outcomes are proposed. Expand
Measuring Neglect
  • P. Hotez
  • Medicine
  • PLoS neglected tropical diseases
  • 2007
TLDR
In this issue of PLoS Neglected Tropical Diseases, a series of articles devoted to NTD disease burden and the controversies about how the chronic and disabling features of these conditions should be best evaluated are begun. Expand
International consultation on long-term global health research priorities, research capacity and research uptake in developing countries
TLDR
The outcomes from this consultation survey provide valuable insights into how DfID stakeholders prioritise research, including the growing importance of non-communicable disease as a global health research priority, being placed above infectious diseases. Expand
Planning to improve global health: the next decade of tuberculosis control.
The Global Plan to Stop TB 2006-2015 is a road map for policy-makers and managers of national programmes. It sets out the key actions needed to achieve the targets of the Millennium Development GoalsExpand
Interventions for the prevention of cardiovascular diseases: a protocol for a systematic review of economic evaluations in low-income and middle-income countries
TLDR
This systematic review protocol has been prepared according to the Preferred Reporting Items for Systematic reviews and Meta-analyses for Protocols (PRISMA-P) 2015 statement and aims to synthesise the current literature on economic evaluations of interventions for primary and secondary cardiovascular disease prevention in LMICs. Expand
Health Gains and Financial Risk Protection Afforded by Treatment and Prevention of Diarrhea and Pneumonia in Ethiopia: An Extended Cost-Effectiveness Analysis
TLDR
Extended cost-effectiveness analysis (ECEA) provides a tool with which to gain a more complete understanding of the health and financial benefits associated with different health policies and interventions, specifically in health gains, FRP and equity benefits. Expand
Global burden of childhood hearing impairment and disease control priorities for developing countries
TLDR
A Viewpoint reviews the implications of this approach in light of the emerging trend toward early detection of childhood hearing impairment as an essential public-health service and in the context of equity, which underpins the global burden of disease initiative. Expand
Official development assistance for health-how neglected are neglected tropical diseases? An analysis of health financing.
TLDR
Analysis of ODA commitments for infectious disease control for the years 2003 to 2007 confirms that Development Assistance Committee (DAC)-countries and multilateral donors have largely ignored funding NTD control projects and supports the call for an increase in funds dedicated to the control of NTDs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Disease Control Priorities in Developing Countries
TLDR
This first edition provides information on disease control interventions for the most common diseases and injuries in developing countries to help them define essential health service packages and offers preventive and case management guidelines critical to improving the quality of care. Expand
Millions Saved: Proven Successes In Global Health
TLDR
A compilation of 17 large scale successful health intervention stories to make the case that some programs have worked / producing major health and welfare benefits that significantly outweigh the costs, and six "wows" that challenge critics of international development assistance. Expand
Intervention Cost-Effectiveness: Overview of Main Messages
TLDR
This chapter provides broad conclusions on the economic efficiency of using these interventions to improve health, and the resulting avertable burden of disease, for 319 interventions covering nearly every disease condition considered in the volume. Expand
Measuring the Global Burden of Disease and Risk Factors, 1990–2001
TLDR
This chapter begins with a brief history of the work on burden of disease, including a discussion of the nature and origins of the disability-adjusted life year (DALY) as a measure of disease burden, and summarizes the methods and findings of the 2001 GBD study. Expand
Priorities in Health
This companion guide to Disease Control Priorities in Developing Countries, second edition, speeds the diffusion of life-saving knowledge by distilling the contents of the larger volume into anExpand
The intolerable burden of malaria: what's new, what's needed. Proceedings of the Third Pan-African MIM Conference. November, 18-20, 2002. Arusha, Tanzania.
TLDR
This supplement aims to strengthen the capacity of scientists and control workers and their institutions to address the burden of malaria through research and development of sciencebased policies and actions in the malarious countries. Expand
Global burden of disease and risk factors
TLDR
Global Burden of Disease and Risk Factors examines the comparative importance of diseases, injuries, and risk factors; it incorporates a range of new data sources to develop consistent estimates of incidence, prevalence, severity and duration, and mortality for 136 major diseases and injuries. Expand
Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence
TLDR
A strong economic case exists for prioritisation of preventive interventions and tuberculosis treatment and where potentially exclusive alternatives exist, cost-effectiveness analysis points to an intervention that offers the best value for money. Expand
Health in an Age of Globalization
Disease has traveled with goods and people since the earliest times. Armed globalization spread disease, to the extent of eliminating entire populations. The geography of disease shaped patterns ofExpand
Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
TLDR
Progress in malaria vaccine research has been substantial over the past five years; 35 candidate malaria vaccines are in development, many of which are in clinical trials, and key to evaluation of vaccine effectiveness will be collection and prompt analysis of epidemiologic information. Expand
...
1
2
...